Please ensure Javascript is enabled for purposes of website accessibility

Why NxStage Medical, Inc. Is Skyrocketing Today

By Brian Feroldi - Updated Aug 7, 2017 at 10:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News that the company has accepted a buyout offer sends shares higher.

What happened

Shares of NxStage Medical (NXTM), a medical device maker focused on end-stage renal disease and acute kidney failure, jumped 28% as of 11:40 a.m. EDT on Monday.

So what

NxStage Medical reported its second-quarter earnings results earlier today. The company's top line grew 5% to $96.2 million while its net loss came in at $2.1 million, or $0.03 per share. These numbers fell a bit short of what market watchers had expected. However, the earnings report is being overshadowed by the news that it has accepted a buyout offer from Fresenius Medical Care (FMS 1.72%).

Fresenius, which is the world's largest provider of dialysis products and services, agreed to acquire NxStage Medical in an all-cash deal worth $2 billion. That translated into a share price of $30 and represents a 30% premium to NxStage Medical's closing price on Friday. Fresenius plans on financing the deal with a combination of cash on hand and through debt.

Businessmen shaking hands and exchanging money

Image source: Getty Images.

Fresenius' management team touted that this acquisition would immediately establish the company as the global leader in home dialysis and provide it with a substantial presence in the U.S. critical care space. Furthermore, the company expects that the deal will be accretive to its net income within three years from closing. 

Rice Powell, Fresenius Medical Care's CEO, offered investors the following rationale on why this deal makes sense for his businesses:

The acquisition supports our 2020 strategic initiative of driving growth in the core business with innovation, better clinical outcomes through Care Coordination and improving the patient experience. Combining our two companies would strengthen and diversify our business in the U.S. and help meet the evolving needs of our patients.

Jeffrey Burbank, NxStage's founder and CEO, was also bullish on the transaction and provided his shareholders with the following commentary:

We believe that the announced transaction with Fresenius Medical Care creates significant value for our shareholders and significant opportunities for our patients, customers, partners and employees. I'm excited about what this means for the future of our products and therapy, and for the patients who will receive greater access to them.

NxStage's board of directors has already unanimously approved the deal. The closing is expected to occur in 2018.

Now what

Fresenius cranked out more than $1.2 billion in net income last year and currently boasts a market cap in excess of $26 billion. Those figures hint that the company should have no problems getting its hands on the $2 billion necessary to finance for this transaction. Since the deal already received the thumbs-up from NxStage's board, it looks to have high odds of closing without much trouble.

NxStage Medical's stock was having a rough 2017 prior to this announcement, declining by double digits since January after management cut its home revenue growth target for the year in its first-quarter results. After today's jump, it is now up by more than 13% since the start of the year.

In total, there are reasons for shareholders on both sides of this deal to applaud this transaction.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool owns shares of and recommends NxStage Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nxstage Medical, Inc. Stock Quote
Nxstage Medical, Inc.
Fresenius Medical Care AG & Co. KGaA Stock Quote
Fresenius Medical Care AG & Co. KGaA
$18.97 (1.72%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.